Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses
US4914021A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Mar 4, 1988 |
| Grant date | Apr 3, 1990 |
| Priority date | — |
| Expiry date | Mar 4, 2008 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/866
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a glycoprotein, carcinoma orosomucoid-related antigen, (CORA), which has a binding affinity for carcinoembryonic antigen (CEA). This glycoprotein is a marker for carcinoma, and can be characteried by having a molecular weight of about 46,000-50,000 daltons, an isoelectric point of about 3.0-3.5, a carbohydrate content of about 25-35% by weight, reactivity with antisera raised thereto, and substantially no reactivity with antisera raised to nonspecific cross-reacting antigen (NCA) or to CEA. Also disclosed are a hybridoma which produces a monoclonal antibody to CORA, the monoclonal antibody to CORA, and a device, kit, and method for detecting and monitoring carcinoma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.